Active surveillance in intermediate risk prostate cancer: is it safe?

by Henk G. van der Poel, Roderick C.N. van den Bergh
Published 2016-06-01

TREXIT Is Now: Should We Abandon the Transrectal Route for Biopsy? A Three-continent Debate—Referee

by Roderick C.N. van den Bergh, Lieke Wever, Harm H.E. van Melick
Published 2021-10-01

Radical Prostatectomy: Sequelae in the Course of Time

by Claudia Kesch, Isabel Heidegger, Veeru Kasivisvanathan, Veeru Kasivisvanathan, Alexander Kretschmer, Giancarlo Marra, Felix Preisser, Derya Tilki, Derya Tilki, Igor Tsaur, Massimo Valerio, Roderick C. N. van den Bergh, Christian D. Fankhauser, Fabio Zattoni, Giorgio Gandaglia
Published 2021-05-01

A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer

by Igor Tsaur, Isabel Heidegger, Jasmin Bektic, Mona Kafka, Roderick C. N. van denBergh, Jarmo C. B. Hunting, Anita Thomas, Maximilian P. Brandt, Thomas Höfner, Eliott Debedde, Constance Thibault, Paola Ermacora, Fabio Zattoni, Silvia Foti, Alexander Kretschmer, Guillaume Ploussard, Severin Rodler, Gunhild vonAmsberg, Derya Tilki, Christian Surcel, Barak Rosenzweig, Moran Gadot, Giorgio Gandaglia, Robert Dotzauer, EAU‐YAU Prostate Cancer Working Party
Published 2021-09-01